Blafarm, I really wonder about dosage and timing of doses too.

First of all, if we are treating S/C, we should dose as Lalezari suggested - intravenously for first dose. Perhaps a week late, 350ml, and a week later, another 350mls.

Pourhassen has said we get 100% CCR5 occupancy with the first dose, even subcutaneously. But if we want better results, the drug should be put into a person's system faster. Occupancy of CCR5 receptors lasts for at least 60 days but new receptors after dosing will appear and not be blockaded. So, another dose a week later for those receptors. A week later, perhaps another dose.

Those later doses wouldn't need to be as strong as the first one it seems to me but prolonged dosing might be a very good thing.

If considerations like this are proven out later, what do you have to do to change the treatment protocols? Lalezari would know. I think I might try to ask him. We haven't heard from him lately and I would really like to hear him weigh in on issues like this and whatever he thinks is important as things have gone along.

I suspect dosage and timing will be quite important in long-haulers. Without adjustments there, Leronlimab may be wasted and effects on symptoms may be less than optimal. Things to consider on our path to approval.